Iovance Raises FY2026 Revenue Guidance to $410-$420M on Strong Amtagvi Demand
IOVA has more than doubled off its 52-week low of $1.76.
Summary
Iovance raised its full-year 2026 revenue guidance to $410-$420 million, a $55 million midpoint increase from the prior $350-$370 million range, and the new outlook tops analyst consensus. The raise is driven by strong U.S. demand for Amtagvi and Proleukin, with management citing record Q2 revenue of $99.3 million and a growing authorized treatment center network of ~100 centers. This follows the company's Q2 earnings beat and prior guidance reaffirmation in July, signaling accelerating commercial traction. The new midpoint implies nearly 60% annual revenue growth and provides visibility into Q3 and Q4. Iovance expects to report Q3 results in early November 2026.
At the time of this announcement, IOVA was trading at $11.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $1.76 to $11.17. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.